Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.
Eur J Cancer
; 157: 153-164, 2021 11.
Article
in En
| MEDLINE
| ID: mdl-34509954
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrimidines
/
Sulfonamides
/
Thyroid Neoplasms
/
Indazoles
/
Iodine Radioisotopes
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Eur J Cancer
Year:
2021
Document type:
Article